Pharmaceutical filing citing a Cancer Cell paper — Tonix Pharmaceuticals, 2025-07-02
Tonix PharmaceuticalsTonix PharmaceuticalsNASDAQ TNXP
Filings SEC · Quote Yahoo cited a paper published in Cancer Cell in a regulatory filing with the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website as a basis for its claims. The company read the way it wrote the paper and the actual scope of the paper in order. The stock price movement for one month after the filing was compared to past cases of the same type and written down where it stood. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure was written in the press release as follows:
A U.S. listed company files a 8-K with the Securities and Exchange Commission when it needs to inform shareholders of material events. The item numbers in the document filed by Tonix Pharmaceuticals on 2025-07-02 were 7.01 Reg FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits. The company cited a paper published in Cancer Cell in the press release attached to the filing. The sentence quoting the paper, copied verbatim from the source, is as follows.
The Cancer Cell publication describes data demonstrating that TFF2-MSA selectively reduces immunosuppressive neutrophils and cancer-driven granulopoiesis. Treatment with TFF2-MSA, in combination with an anti-PD1 antibody, induced robust anti-tumoral CD8+ T cell responses, inhibiting tumor invasion.
What a reader should first check is where the company placed the paper in the press release. Next, the reader should determine whether the paper supports the entire company claim or only a part of it. To answer the latter question, one must read the full paper. This article, which reads only the abstract, cannot answer that.
The scope of the paper mentioned in the abstract is limited to this.
The paper's title is A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis and it was published in Cancer Cell on 2025-06-26. The authors are affiliated with Columbia University Irving Medical Center · CSIRO Health and Biosecurity · New York University · Fujian Medical University. The summary at the beginning of the paper is called abstract. What this article has read is only up to that point. This paragraph was written by a person after filtering out a draft written by a machine that read the abstract, and it is of a different grade than a full-text reading and original judgment.
The abstract of this paper is not publicly available, so it has not been summarized. What can be known from the title is that it is an experimental study showing that a CXCR4 partial agonist targets neutrophils that suppress immunity within tumors to enhance the effectiveness of immunotherapy. It is not possible to determine whether this is a human trial or an animal experiment based on the title alone.
What the abstract does not answer remains in the full text and appendices. This article, which has not gone beyond that, leaves the blanks as they are. Readers should compare the two citations above to determine which sentence in the abstract corresponds to the cited passage by the company.
One month later, the stock price was within the upper quartile of the sample.
The remaining return, after subtracting the portion that moves with the overall market, is called excess return. The date is written as a trading day, counting only the days the stock market is open. In calendar terms, 20 trading days are approximately one month. The excess return for the day of the regulatory filing and the following month are listed in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| Five trading days before the filing | +4.9% | The extent of movement before the filing |
| On the day of the filing | −7.3% | On the filing day or the first trading day after |
| Accumulated over +1 to +5 trading days | +9.1% | One week |
| Cumulative +1~+20 trading days | +8.3% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of +8.3% for this case is in the top quarter, corresponding to the 79% position from the bottom among 142 samples.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | median | top 25% | top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.9% | −20.1% | −7.4% | +5.5% | +19.5% | +8.3% |
Half of the sample falls between the two central marks in the chart. One checks from the chart whether this case lies within or outside. The sample collects cases where U.S. listed companies wrote papers in 8-K over the past ten years. The company itself is excluded from the sample. The numbers written here are past facts, not rules applicable to the next case.
There are 23 additional cases where the same company wrote papers in 8-K, and they are placed together in the table below.
| Disclosure date | the journal of the paper | excess return for one month |
|---|---|---|
| 2018-01-22 | PLoS ONE | −15.3% |
| 2020-12-04 | Genome biology | +20.9% |
| 2020-12-23 | Genome biology | +32.1% |
| 2021-11-23 | JCI Insight | −11.5% |
| 2021-12-14 | JCI Insight | −23.9% |
| 2022-01-04 | JCI Insight | −38.1% |
| 2022-01-11 | JCI Insight | −31.8% |
| 2022-03-14 | Nature Structural & Molecular Biology | −9.3% |
after the filing, the company issued such documents
after the filing date, the company issued three 8-K filings. Only the item numbers are listed here. In 8-K filings without titles, the item numbers indicate the type of content, as the numbers specify whether it was an earnings announcement or a contract. The specific event is read in the original text of each link.
- 2025-07-09 8-K Items 7.01, 8.01, 9.01 — Reg FD disclosure · Other events · Financial statements and exhibits
- 2025-07-10 8-K Items 7.01, 8.01, 9.01 — Reg FD disclosure · Other events · Financial statements · Exhibits
- 2025-07-16 8-K Items 7.01, 8.01, 9.01 — Reg FD disclosure · Other events · Financial statements · Exhibits
What this article does not answer
This article, which reads only abstracts, cannot answer how the paper reviewed what methods and what results it showed. How often the paper cited by the company was cited afterwards can be checked again through the citation count on OpenAlexOpenAlex
Data source · Website. What will be seen next is whether the company's next 8-K again cites the same paper.
Term explanation
- 8-K
- A periodic report submitted to the Securities and Exchange Commission when a listed company in the United States has something to inform its shareholders. The types are indicated by item numbers such as earnings, contracts, and executive changes. All events in this article are derived from this document.
- Excess return
- The remainder obtained by subtracting the overall market return from the stock return. It is used to observe the movement of the company alone after removing the portion where the market as a whole rises or falls.
- Trading day
- A date counted only on days when the stock market is open. Since weekends and holidays are excluded, 20 trading days amount to roughly a calendar month.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details and limitations of the method.